BACKGROUND: Our aim was to assess, in obese patients undergoing Roux-en Y gastric bypass surgery, the cumulative Helicobacter pylori (HP) eradication rates in two consecutive time spans (2006-2008 and 2009-2010). METHODS: The study adopted a 14-day clarithromycin-based triple therapy in first-line treatment as proposed by the Maastricht III consensus-proton pump inhibitor bid, clarithromycin 500 mg bid and amoxicillin 1,000 mg bid-and a 14-day second-line levofloxacin-based empirical regimen-proton pump inhibitor bid, amoxicillin 1,000 mg bid and levofloxacin 500 mg od. RESULTS: In 2006-2008, 253 patients received first-line therapy. HP was eradicated in 200 patients and 14 patients withdrew (intention to treat (ITT) = 79.1 %; per protocol (PP) = 83.7 %). In the remaining 39 patients, HP was eradicated in 22 patients and 8 patients withdrew (ITT = 56.4 % and PP = 71.0 %). Thus, out of 253 patients, HP was eradicated in 222 patients, 22 patients withdrew and 9 remained positive. In 2009-2010, 437 patients received first-line therapy. HP was eradicated in 256 patients and 30 patients withdrew (ITT = 58.6 %; PP = 62.9 %). In the remaining 151 patients, HP was eradicated in 80 and 6 patients withdrew (ITT = 53.0 % and PP = 55.1 %). These results give cumulative eradication rates of 87.7 % ITT and 96.1 % PP (2006-2008) and of 76.9 % ITT and 83.8 % PP (2009-2010). CONCLUSIONS: Cumulative HP eradication rates have fallen during 2006-2010 due to the fall of first-line eradication therapy rate, which was around 20 %. Therefore, the first-line clarithromycin-based Maastricht III consensus eradication is no longer effective in bariatric patients indicating the need to test new regimens.
BACKGROUND: Our aim was to assess, in obesepatients undergoing Roux-en Y gastric bypass surgery, the cumulative Helicobacter pylori (HP) eradication rates in two consecutive time spans (2006-2008 and 2009-2010). METHODS: The study adopted a 14-day clarithromycin-based triple therapy in first-line treatment as proposed by the Maastricht III consensus-proton pump inhibitor bid, clarithromycin 500 mg bid and amoxicillin 1,000 mg bid-and a 14-day second-line levofloxacin-based empirical regimen-proton pump inhibitor bid, amoxicillin 1,000 mg bid and levofloxacin 500 mg od. RESULTS: In 2006-2008, 253 patients received first-line therapy. HP was eradicated in 200 patients and 14 patients withdrew (intention to treat (ITT) = 79.1 %; per protocol (PP) = 83.7 %). In the remaining 39 patients, HP was eradicated in 22 patients and 8 patients withdrew (ITT = 56.4 % and PP = 71.0 %). Thus, out of 253 patients, HP was eradicated in 222 patients, 22 patients withdrew and 9 remained positive. In 2009-2010, 437 patients received first-line therapy. HP was eradicated in 256 patients and 30 patients withdrew (ITT = 58.6 %; PP = 62.9 %). In the remaining 151 patients, HP was eradicated in 80 and 6 patients withdrew (ITT = 53.0 % and PP = 55.1 %). These results give cumulative eradication rates of 87.7 % ITT and 96.1 % PP (2006-2008) and of 76.9 % ITT and 83.8 % PP (2009-2010). CONCLUSIONS: Cumulative HP eradication rates have fallen during 2006-2010 due to the fall of first-line eradication therapy rate, which was around 20 %. Therefore, the first-line clarithromycin-based Maastricht III consensus eradication is no longer effective in bariatric patients indicating the need to test new regimens.
Authors: M Fried; V Hainer; A Basdevant; H Buchwald; M Deitel; N Finer; J W M Greve; F Horber; E Mathus-Vliegen; N Scopinaro; R Steffen; C Tsigos; R Weiner; K Widhalm Journal: Int J Obes (Lond) Date: 2007-02-27 Impact factor: 5.095
Authors: P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers Journal: Gut Date: 2006-12-14 Impact factor: 23.059
Authors: P Malfertheiner; F Mégraud; C O'Morain; D Bell; G Bianchi Porro; M Deltenre; D Forman; G Gasbarrini; B Jaup; J J Misiewicz; J Pajares; M Quina; E Rauws Journal: Eur J Gastroenterol Hepatol Date: 1997-01 Impact factor: 2.566
Authors: Rute Maria Cerqueira; M Conceição Manso; Manuel R Correia; Carolina D Fernandes; Hélder Vilar; Mário Nora; Paulo Martins Journal: Obes Surg Date: 2011-09 Impact factor: 4.129
Authors: J P Gisbert; J-L Gisbert; S Marcos; I Jimenez-Alonso; R Moreno-Otero; J M Pajares Journal: Aliment Pharmacol Ther Date: 2007-11-12 Impact factor: 8.171
Authors: John J Kelly; Richard A Perugini; Qi L Wang; Donald R Czerniach; Julie Flahive; Philip A Cohen Journal: Surg Endosc Date: 2015-01-01 Impact factor: 4.584
Authors: Nuno Almeida; Maria Manuel Donato; José Manuel Romãozinho; Cristina Luxo; Olga Cardoso; Maria Augusta Cipriano; Carol Marinho; Alexandra Fernandes; Carlos Calhau; Carlos Sofia Journal: BMC Gastroenterol Date: 2015-02-15 Impact factor: 3.067